Provided by Tiger Trade Technology Pte. Ltd.

Madrigal Pharmaceuticals

546.19
-8.3800-1.51%
Post-market: 545.91-0.2800-0.05%17:42 EST
Volume:239.77K
Turnover:131.82M
Market Cap:12.40B
PE:-41.90
High:561.00
Open:551.90
Low:544.85
Close:554.57
52wk High:605.00
52wk Low:265.00
Shares:22.71M
Float Shares:11.00M
Volume Ratio:0.92
T/O Rate:2.18%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-13.0355
EPS(LYR):-21.9007
ROE:-41.22%
ROA:-15.78%
PB:19.82
PE(LYR):-24.94

Loading ...

Cantor Fitzgerald Upgrades Madrigal Pharmaceuticals to Overweight From Neutral

MT Newswires Live
·
Nov 05

Madrigal Pharmaceuticals: Strong Market Performance and Strategic Positioning Drive Buy Rating

TIPRANKS
·
Nov 05

Stock Track | Madrigal Pharmaceuticals Soars 5.19% on Strong Q3 Revenue Growth and Rezdiffra Demand

Stock Track
·
Nov 04

Stock Track | Madrigal Pharmaceuticals Soars 5.19% on Strong Q3 Revenue Growth and Rezdiffra Demand

Stock Track
·
Nov 04

Stock Track | Madrigal Pharmaceuticals Plunges 7.85% Pre-market on Wider-than-Expected Q3 Loss

Stock Track
·
Nov 04

Stock Track | Madrigal Pharmaceuticals Soars 6.34% Pre-Market on Strong Q3 Revenue Growth and Rezdiffra Demand

Stock Track
·
Nov 04

Stock Track | Madrigal Pharmaceuticals Soars 6.34% Pre-market on Strong Q3 Revenue and Promising Outlook

Stock Track
·
Nov 04

Madrigal Pharma Q3 revenue rises on Rezdiffra demand

Reuters
·
Nov 04

Earnings Flash (MDGL) Madrigal Pharmaceuticals Posts Q3 Net Loss $5.08 a Share, vs. FactSet Est of $2.29 Loss

MT Newswires Live
·
Nov 04

Madrigal Pharmaceuticals Q3 EPS $(5.08) Misses $(2.16) Estimate, Sales $287.268M Beat $245.386M Estimate

Benzinga
·
Nov 04

BRIEF-Madrigal Pharmaceuticals Q3 EPS USD -5.08

Reuters
·
Nov 04

Biotech Stocks Are Coming Back. Here's What's Driving The Sector Higher.

Dow Jones
·
Nov 04

Madrigal Pharmaceuticals' Liver Disease Treatment Rezdiffra Outperforms Early Cautious Outlook, BofA Says

MT Newswires Live
·
Nov 04

Biotech is back. Here's why these rallying stocks belong in your portfolio now.

Dow Jones
·
Nov 03

Madrigal Pharmaceuticals Raised to Neutral From Underperform by B of A Securities

Dow Jones
·
Nov 03

Madrigal Pharmaceuticals upgraded to Neutral at BofA after Rezdiffra outperforms

TIPRANKS
·
Nov 03

Madrigal to Present New Data from the Company’s MASH Program at AASLD’s The Liver Meeting 2025

GlobeNewswire
·
Oct 28

Rezdiffra’s Surging Sales and Extended Patent Exclusivity Could Be a Game Changer for Madrigal (MDGL)

Simply Wall St.
·
Oct 28

Madrigal Pharmaceuticals to Release Third-Quarter 2025 Financial Results and Host Webcast on November 4, 2025

GlobeNewswire
·
Oct 22

BRIEF-Madrigal Pharmaceuticals Announces Grants Of Inducement Awards Under Nasdaq Listing Rule 5635(C)(4)

Reuters
·
Oct 22